Table 1. Patient characteristics.
| Patients (n=19) | N (%) or median (min-max) |
|---|---|
| Age, years | 62 (38-77) |
| Menopausal status | |
| Pre-menopausal | 2 (11 %) |
| Post-menopausal | 17 (89 %) |
| Ethnicity | |
| Not Hispanic or Latino | 19 (100 %) |
| Race | |
| White | 16 (84 %) |
| Black or African American | 2 (11 %) |
| American Indian or Alaska Native | 1 (5 %) |
| Histology (primary diagnosis) | |
| Invasive ductal | 15 (79 %) |
| Invasive lobular | 1 (5 %) |
| Mixed ductal and lobular | 2 (11 %) |
| Unknown | 1 (5 %) |
| De novo stage IV | |
| Yes | 5 (26 %) |
| No | 14 (74 %) |
| ER (primary diagnosis) | |
| Positive | 18 (95 %) |
| Weakly positive | 1 (5 %) |
| PgR (primary diagnosis) | |
| Positive | 5 (26 %) |
| Weakly positive | 8 (43 %) |
| Negative | 5 (26 %) |
| Unknown | 1 (5 %) |
| HER2neu (primary diagnosis) | |
| Positive | 1 (5 %) |
| Negative | 15 (79 %) |
| Unknown | 3 (16 %) |
| Prior adjuvant chemotherapy | |
| Yes | 12 (63 %) |
| No | 7 (37 %) |
| Prior adjuvant radiation | |
| Yes | 10 (53 %) |
| No | 8 (42 %) |
| Unknown | 1 (5 %) |
| Prior adjuvant endocrine therapy | |
| Aromatase inhibitor (AI) | 6 (31 %) |
| AI and tamoxifen | 2 (11 %) |
| Tamoxifen | 2 (11 %) |
| None | 9 (47 %) |
| Number of lesions (FES PET dynamic FOV) | |
| 1 | 2 (11 %) |
| 2-3 | 11 (57 %) |
| 4-5 | 6 (32 %) |
| Number of lesions (FES PET sweep) | |
| 1 | 1 (5 %) |
| 2-4 | 5 (26 %) |
| 5-7 | 6 (32 %) |
| 8-12 | 7 (37 %) |
| Study treatment | 4(21 %) |
| Tamoxifen | 3 (16 %) |
| Anastrozole | 1 (5 %) |
| Exemestane + fulvestrant | 4 (21 %) |
| Letrozole | 4 (21 %) |
| Letrozole + fulvestrant | 1 (5 %) |
| Fulvestrant | 2 (11 %) |
| Did not undergo endocrine treatment on study | |
| Biopsy Results (n=15) | |
| ER (metastatic lesion) | |
| Positive | 10 (67 %) |
| Weakly positive | 2 (13 %) |
| Negative | 3 (20 %) |
| PgR (metastatic lesion) | |
| Positive | 6 (40 %) |
| Weakly positive | 4 (27 %) |
| Negative | 4 (27 %) |
| Unknown | 1 (6 %) |
| HER2neu (metastatic lesion) | |
| Positive | 3 (20 %) |
| Negative | 8 (53 %) |
| Unknown | 4 (27 %) |
| Clinical response | |
| Partial response | 4 (21 %) |
| Stable disease | 45 (216 %) |
| Radiographic progressive disease | 76 (372 %) |
| No response assessmentc | 4 (21 %) |
a
One patient also underwent ovarian suppression
b
When Allred scores were available, scoring was 0 “negative,” 2–6 “weakly positive,” 7–8 “positive.” When Allred scores were not available, clinical report scores of 1+ were “weakly positive”
c
Includes two patients who did not undergo endocrine monotherapy, one who had complications from a non-breast cancer-related surgery after 2 days of anastrozole, and one who changed therapy (from tamoxifen) when a successful metastatic biopsy revealed ER- disease